儿科患者异基因造血干细胞移植后间充质基质细胞植入情况分析：一项大型多中心研究

Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study.

作者信息

Castello Laura M, Leone Marco, Adamini Aloe, Castiglia Sara, Mareschi Katia, Ferrero Ivana, Marco De Gobbi, Carnevale-Schianca Fabrizio, Fagioli Franca, Berger Massimo

机构信息

Department of Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, City of Science and Health of Turin, Regina Margherita Children's Hospital, Turin.

Departments of Public Health and Pediatrics.

出版信息

J Pediatr Hematol Oncol. 2018 Nov;40(8):e486-e489. doi: 10.1097/MPH.0000000000001305.

DOI:10.1097/MPH.0000000000001305

PMID:30188352

Abstract

The mesenchymal stem cell (MSC) role after allogeneic hematopoietic stem cell transplantation (HSCT) is still a matter of debate; in particular, MSC engraftment in recipient bone marrow (BM) is unclear. A total of 46 patients were analyzed for MSC and hemopoietic stem cell engraftment after HSCT. The majority of patients had the BM as the stem cell source, and acute leukemia was the main indication for HSCT. Mesenchymal and hematopoietic stem cell chimerism analysis was carried out through specific polymorphic tandemly repeated regions. All patients reached complete donor engraftment; no evidence of donor-derived MSC engraftment was noted. Our data indicate that MSCs after HSCT remain of recipient origin despite the following: (i) myeloablative conditioning; (ii) the stem cell source; (iii) the interval from HSCT to BM analysis; (iv) the underlying disease before HSCT; and (v) the patients' or the donors' age at HSCT.

摘要

间充质干细胞（MSC）在异基因造血干细胞移植（HSCT）后的作用仍存在争议；尤其是，MSC在受体骨髓（BM）中的植入情况尚不清楚。对46例HSCT后的患者进行了MSC和造血干细胞植入分析。大多数患者以BM作为干细胞来源，急性白血病是HSCT的主要适应证。通过特定的多态性串联重复区域进行间充质和造血干细胞嵌合分析。所有患者均实现完全供体植入；未发现供体来源的MSC植入的证据。我们的数据表明，HSCT后的MSC尽管存在以下情况，但仍来源于受体：（i）清髓预处理；（ii）干细胞来源；（iii）从HSCT到BM分析的间隔时间；（iv）HSCT前的基础疾病；以及（v）HSCT时患者或供体的年龄。